Skip to main content
. 2016 May 19;7(26):40073–40084. doi: 10.18632/oncotarget.9484

Figure 3. Everolimus does not inhibit Met phosphorylation in human everolimus resistant cancer cell lines.

Figure 3

A. Percent of cell density of 786-O, 786-O EveR and HCT116 cells treated for 72 hours with everolimus (0.1–2.5 μM), as measured by MTT assay. Data represent the mean (±SD) of three independent experiments, each performed in triplicate. Bars, SDs. B. Western blot analysis of protein expression in 786-O EveR and HCT116 cells treated for 24 hours with everolimus (0.5 μM). The relative optical density of phospho-protein levels normalized to total protein levels is shown. C. Immunoprecipitation assay: 786-O EveR and HCT116 cells, cultured in complete medium and treated for 24 hours with everolimus (0.5 μM), were immunoprecipitated using anti-Met antibody and blotted with anti-Met and an anti-FKBP12 antibodies. The same samples with normal IgG served as negative control.